Last €55.25 EUR
Change Today +1.50 / 2.79%
Volume 6.7K
As of 11:32 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (ZEG) Snapshot

Open
€53.31
Previous Close
€53.75
Day High
€55.27
Day Low
€53.31
52 Week High
05/19/14 - €64.20
52 Week Low
10/10/13 - €36.61
Market Cap
69.8B
Average Volume 10 Days
3.3K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/14
P/E TM
--
Dividend
€3.03
Dividend Yield
4.13%
Current Stock Chart for ASTRAZENECA PLC (ZEG)

astrazeneca plc (ZEG) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; and Qiagen N.V. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

Founded in 1992

astrazeneca plc (ZEG) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (ZEG) Key Developments

Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology

Illumina, Inc. announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca, Janssen Biotech, Inc., and Sanofi. Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners' clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm.

AstraZeneca Introduces Oral Medication for Type 2 Diabetes

AstraZeneca announced the launch of its new once-daily oral medication to aid Filipino adult patients with type 2 diabetes manage their condition better through the removal of excess glucose and its associated calories in the urine. Diabetes is a chronic progressive disease that is complex to manage. Most of the Filipino patients with diabetes are struggling to control their blood sugar levels, as well as its co-morbidities such as weight, blood pressure and blood cholesterol. 85% of Filipino patients with type 2 diabetes, blood sugar remains uncontrolled. Apart from poor blood glucose control, it has been reported that Asian patients contract the disease at a younger age, making them at a higher risk of developing long-term complications resulting in higher rates of morbidity and early mortality. As a result of the difficulty to change Filipino's food consumption and attitude towards physical activity, weight management then becomes an issue. In the country, it has been reported that seven out of 10 adults with type 2 diabetes are overweight and obese. Recognizing the difficulties being experienced by adult patients with type 2 diabetes, AstraZeneca has developed a new oral medication that will aid Filipinos with Diabetes manage their situation better. The oral medication, Dapagliflozin, developed by AstraZeneca and Bristol-Myers Squibb Company, is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help flush out surplus sugar, thus reducing blood sugar levels.

AstraZeneca Announces United States Department of Justice Closes Investigation into PLATO Clinical Trial for Brilinta

AstraZeneca announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor). The government is not planning any further action. AstraZeneca recently announced the start of the SOCRATES trial, studying Brilinta for patients with acute ischemic stroke or transient ischemic attack, and the THEMIS study in patients with Type 2 diabetes and coronary atherosclerosis. These studies form part of PARTHENON, AstraZeneca's large ever clinical trial programme, involving more than 80,000 patients worldwide. The programme also includes two trials that have recently completed recruitment; EUCLID for patients with Peripheral Artery Disease and PEGASUS, studying Brilinta for secondary prevention in patients with previous myocardial infarction. Headline results for PEGASUS are expected in the first quarter of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €55.25 EUR +1.50

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEG.
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
No financial data is available for ZEG.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.